Factors related to the improvement in quality of life for depressed inpatients treated with fluoxetine

BMC Psychiatry

Table 3 Pre-post comparisons of HAMD-17^a and SF-36^b for patients completing the 6-week treatment (n = 106)

Measure	Taiwanese norms (Mean ± SD)	Week 0 (Mean ± SD)	Week 6 (Mean ± SD)	Difference (Mean ± SD)	p	Effect size
HAMD-17		31.4 ± 6.4	13.7 ± 8.3	−17.7 ± 8.5	<0.001*	−2.093
SF-36
Physical functioning	92.24 ± 16.16	61.5 ± 25.7	63.9 ± 25.4	2.4 ± 23.7	0.299	0.101
Role physical limitations	83.65 ± 33.27	15.1 ± 30.8	28. 5 ± 41.9	13.4 ± 45.1	0.003*	0.298
Bodily pain	84.84 ± 19.42	45.3 ± 26.1	50.9 ± 29.2	5.6 ± 24.1	0.018*	0.233
General Health	69.29 ± 21.27	28.0 ± 22.5	35.9 ± 26.4	7.9 ± 22.8	<0.001*	0.348
Vitality	68.27 ± 18.66	24.6 ± 19.6	33.7 ± 23.2	9.2 ± 21.9	<0.001*	0.417
Social functioning	86.81 ± 17.05	33.8 ± 22.9	43.0 ± 26.2	9.2 ± 27.2	<0.001*	0.338
Role emotional limitations	79.40 ± 36.07	5.7 ± 17.5	23.3 ± 39.1	17.6 ± 40.0	<0.001*	0.441
Mental health	73.01 ± 16.55	26.7 ± 19.3	37.6 ± 22.2	10.9 ± 23.9	<0.001*	0.457
Physical component summary		39.3 ± 10.0	40.6 ± 10.6	1.3 ± 9.3	0.148	0.142
Mental component summary		23.3 ± 8.62	29.7 ± 11.3	6.4 ± 11.6	<0.001*	0.548

ISSN: 1471-244X